ARTICLE | Company News
Lundbeck, Merck deal
July 5, 2004 7:00 AM UTC
The partners expanded a February deal to develop and commercialize in the U.S. LUN's gaboxadol GABA A receptor agonist, which is in Phase III testing in Canada and Europe to treat sleep disorders (se...